Prelude Therapeutics Incorporated (PRLD)

3,7900 -0,1400 (-3,56%) Al cierre: 04:00PM EDT

Prelude Therapeutics Incorporated

175 Innovation Boulevard
Wilmington, DE 19805
United States
302 467 1280
https://preludetx.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 128

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Krishna Vaddi D.V.M., Ph.D.	Founder, CEO & Director	905,92k	N/A	1966
Dr. Edna Huang M.D.	President & Chief Medical Officer	865,63k	N/A	1973
Mr. Bryant David Lim J.D.	Interim CFO, Chief Legal Officer & Corporate Secretary	586,42k	N/A	1971
Ms. Aimee Crombie Ph.D.	Senior VP and Head of Strategic Planning & Operations	N/A	N/A	N/A
Dr. Madhu Pudipeddi Ph.D.	Senior Vice President of Technical Operations	N/A	N/A	N/A
Dr. Peggy A. Scherle Ph.D.	Chief Scientific Officer	868,62k	N/A	1962
Lindsey Trickett	Vice President of Investor Relations	N/A	N/A	N/A
Ms. Michele Porreca M.B.A.	Chief People Officer	N/A	N/A	N/A
Dr. Andrew P. Combs Ph.D.	Executive VP & Chief Chemistry Officer	562,46k	N/A	1967
Mr. Naveen Babbar Ph.D.	Senior Vice President of Translation Medicine	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Gobierno corporativo

El ISS Governance QualityScore de Prelude Therapeutics Incorporated, a día 1 de junio de 2024, es 9. Las puntuaciones base son Auditoría: 7; Tablero: 6; Derechos de los accionistas: 10; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.